PAB TOO CHEAP? “The deals in the six months have been insane,”

In September, Gilead Sciences (NASDAQ:GILD) agreed to pay an eye-popping $US21 billion for Immunomedics (NASDAQ:IMMU), while Merck & Co (NYSE:MRK) committed $US4.2 billion to Seattle Genetics (NASDAQ:SGEN).

“The deals in the six months have been insane,” Campbell told *. “Where we are compared to a year ago, the number of deals is going through the roof.”

The Melbourne company’s research is much less far along than that Immunomedics or Seattle Genetics, as its tumour-fighting therapy still has not yet been tested in humans.

But Campbell said the Yale University-licensed drug is the first biologic drug that can cross the blood-brain barrier, binding to the nuclei of cancer cells and inhibiting what’s known as the DNA damage response (DDR) mechanism.

“It has a very unique way of killing cancer cells,” he said. “It really doesn’t matter what type of cancer is there.”

https://unauthorised investment advice/health/which-cancer-fighting-biotech-will-be-the-next-race-oncology/